Recent Updates
Recently added Catalysts
XLO

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

Key Takeaway: WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate virtually in a fireside chat at
Price reaction · baseline $28.98 (2022-09-02 close) · hit after-hours · clean, no other XLO news in the window
day 0 close
+8.2%
day 1
+8.2%
day 3 · peak
+32.9%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
21.2%
average across 4 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
XTX501
Phase 1 · Metastatic NSCLC - Non-Small Cell Lung Cancer

Full Press Release Details

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate virtually in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 2:55 p.m. ET.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.
About Xilio Therapeutics
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
For Investor Inquiries:
For Media Inquiries:
Last updated: Sep 6, 2022